Tributary Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Tributary Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-29,900	Closed	-$1.05M	–	190
2022 Q1	$1.05M	Sell	29,900 -6,000	-17%	-$201K	0.08%	122
2021 Q4	$1.5M	Sell	35,900 -5,000	-12%	-$203K	0.11%	129
2021 Q3	$2.01M	Hold	40,900	–	–	0.16%	115
2021 Q2	$1.71M	Buy	+40,900	New	+$1.59M	0.13%	126

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Tributary Capital Management's MRVI Position: Q2 2022 in Review

Tributary Capital Management sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 29,900 shares — an estimated $1.05M sold.

Tributary Capital Management first reported a position in MRVI in Q2 2021 and held it in 4 quarters. The position peaked at $2.01M in Q3 2021. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

Tributary Capital Management reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
Tributary Capital Management sold 29,900 Maravai LifeSciences shares in Q2 2022, an estimated $1.05M.
Tributary Capital Management first reported a position in Maravai LifeSciences in Q2 2021 and held it in 4 quarters.
Tributary Capital Management's Maravai LifeSciences position peaked at $2.01M in Q3 2021.
216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Tributary Capital Management's 13F filing for Q2 2022, filed 19 Jul 2022.